|Articles|January 28, 2016
Niche Service Providers Alliance Offers New Outsourcing Model
The alliance’s primary goal is to be flexible and adaptive based on client needs, while mitigating client risk, driving efficiency and improving timelines, and removing barriers that prevent getting treatments to market in a timely fashion.
Advertisement
A consortium of clinical trial management experts has formed to provide an alternative outsourcing solution for the pharmaceutical, biotech, and medical device industries. The alliance will leverage the strengths of each member organization, which deliver expertise across all functional areas that comprise the R&D organization.
Clients will be provided one point of contact. That contact--functioning as a project manager/director--will oversee all member companies to ensure the project is seamlessly executed and providing full transparency to the client, as needed.
Contractually, clients will receive one proposal and one contract for their project, minimizing the management of multiple vendors. Additionally, the client would only receive one invoice, with consortium members working on the financials on the back end.
The alliance’s primary goal is to be flexible and adaptive based on client needs, while mitigating client risk, driving efficiency and improving timelines, and removing barriers that prevent getting treatments to market in a timely fashion.
Companies that comprise this consortium to date include Clincierge, FMD K&L, InSeption Group, LLC, OneSource Regulatory, LLC, and Pyxa Solutions, LLC with room to grow. Contact jarcangelo@inseptiongroup.com to learn more.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5